OPTHEA LIMITED - Charts / Financials

Market Cap $855.6M Add to my watchlist

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

REFRESH

Last update - 15.59pm 15/11/2024 (20 minute delay)

Day
Open	69.5¢		Day High	69.5¢		Day Low	63.0¢
Daily Volume	4305102

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
1	65.5¢	49996		6	66.0¢	50869

Directors & Senior Management

Dr. Frederic Guerard	Chief Executive Officer
Mr. Daniel E. Geffken	Interim Chief Financial Officer
Mr. Peter F. Lang	Chief Financial Officer
Dr. Julie Clark	Senior Vice President - Clinical Development
Mr. Bruno Gagnon	Senior Vice President - Global Clinical Operations
Dr. Dayong Li	Senior Vice President - Biometrics
Dr. Fang Li	Senior Vice President - Regulatory Affairs
Mrs. Karen Adams	Vice President - Finance, Company Secretary
Mr. Anthony Bonifazio	Vice President - Market Access
Dr. John Han	Vice President - Medical Affairs
Dr. Jeremy Max Levin	Non-Executive Independent Chairman of the Board
Mr. Sujal A. Shah	Non-Executive Director
Mr. Anshul Thakral	Non-Executive Director
Mr. Lawrence Gozlan	Non-Executive Independent Director
Dr. Julia A. Haller	Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last 65.5¢		Change -0.045(6.43%)		Mkt cap ! $855.6M

Open	High	Low	Value	Volume
69.5¢	69.5¢	63.0¢	$2.808M	4.305M

Buyers (Bids)

No.	Vol.	Price($)
1	49996	65.5¢

Sellers (Offers)

Price($)	Vol.	No.
66.0¢	50869	6

View Market Depth

No.	Vol.	Price($)
4	45916	0.590
2	37273	0.585
3	38706	0.580
2	108695	0.575
3	44061	0.570

Price($)	Vol.	No.
0.600	10000	1
0.605	47182	2
0.610	42308	4
0.615	1600	1
0.620	130700	4

Last trade - 16.10pm 15/11/2024 (20 minute delay)


Last 65.0¢		Change -0.045 ( 8.37 %)
Open	High	Low	Volume
69.5¢	69.5¢	63.5¢	1694402
Last updated 15.59pm 15/11/2024 ?

OPT (ASX) Chart